Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Drugs
New class of platinum-based antitumorals may improve outcomes in cancer patients
February 2nd, 2006
A new class of platinum-based antitumorals may improve clinical outcomes in cancer patients. "The first pi-conjugated macrocyclic diimine and triaza DNA-binding intercalators and their platinum(II) conjugates have been synthesized by direct Schiff base cyclocondensation. The in vitro anticancer activities of compounds 3, 4, and 5 were tested on 5 cancer cell lines: MCF-7, A549, P388, A2780, and A2780cisR," scientists reported in the Journal of Medicinal Chemistry. "Ovarian tumors were included specifically to evaluate the new conjugates' ability to circumvent A2780cisR resistance. Antitumor effects of the newly conjugated compounds were...
Source: Women's Health Weekly (2006-02-02)
|
